FOLFIRI regimen as second-/third-line chemotherapy in patients with advanced pancreatic adenocarcinoma refractory to gemcitabine and platinum salts: A retrospective series of 70 patients.

被引：0
|
作者：
Neuzillet, C.
Hentic, O.
Rousseau, B.
Rebours, V.
Bengrine-Lefevre, L.
Bonnetain, F.
Raymond, E.
Ruszniewski, P.
Louvet, C.
Hammel, P.
机构：
[1] Hop Beaujon, Clichy La Garenne, France
[2] Hop St Antoine, F-75571 Paris, France
[3] Ctr Georges Francois Leclerc, Dijon, France
[4] Beaujon Univ Hosp, Clichy, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.4132
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4132
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Efficacy of the third-line chemotherapy in patients with advanced pancreatic cancer.
    Kim, Bomi
    Ahn, Jinwoo
    Jung, Jae Hyup
    Jung, Kwangrok
    Lee, Jong-Chan
    Hwang, Jin-Hyeok
    Kim, Jaihwan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 711 - 711
  • [12] Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study
    Shimpei Maeda
    Fuyuhiko Motoi
    Tohru Onogawa
    Takanori Morikawa
    Ottomo Shigeru
    Naoaki Sakata
    Tatsuyuki Takadate
    Takeshi Naitoh
    Toshiki Rikiyama
    Yu Katayose
    Shinichi Egawa
    Michiaki Unno
    International Journal of Clinical Oncology, 2011, 16
  • [13] Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study
    Maeda, Shimpei
    Motoi, Fuyuhiko
    Onogawa, Tohru
    Morikawa, Takanori
    Shigeru, Ottomo
    Sakata, Naoaki
    Takadate, Tatsuyuki
    Naitoh, Takeshi
    Rikiyama, Toshiki
    Katayose, Yu
    Egawa, Shinichi
    Unno, Michiaki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2011, 16 (05) : 539 - 545
  • [14] Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
    Se Jun Park
    Hyunho Kim
    Kabsoo Shin
    Myung Ah Lee
    Tae Ho Hong
    World Journal of Gastrointestinal Oncology, 2019, (11) : 1021 - 1030
  • [15] Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
    Park, Se Jun
    Kim, Hyunho
    Shin, Kabsoo
    Lee, Myung Ah
    Hong, Tae Ho
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2019, 11 (11) : 1021 - 1030
  • [16] Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature
    ter Veer, Emil
    Mohammad, Nadia Haj
    van Valkenhoef, Gert
    Ngai, Lok Lam
    Mali, Rosa M. A.
    van Oijen, Martijn G. H.
    van Laarhoven, Hanneke W. M.
    CANCER AND METASTASIS REVIEWS, 2016, 35 (03) : 439 - 456
  • [17] Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature
    Emil ter Veer
    Nadia Haj Mohammad
    Gert van Valkenhoef
    Lok Lam Ngai
    Rosa M. A. Mali
    Martijn G. H. van Oijen
    Hanneke W. M. van Laarhoven
    Cancer and Metastasis Reviews, 2016, 35 : 439 - 456
  • [18] Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study
    Viaud, Juliette
    Brac, Clemence
    Artru, Pascal
    Le Pabic, Estelle
    Leconte, Berengere
    Bodere, Anais
    Pracht, Marc
    Le Sourd, Samuel
    Edeline, Julien
    Lievre, Astrid
    DIGESTIVE AND LIVER DISEASE, 2017, 49 (06) : 692 - 696
  • [19] Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases
    He, Yayi
    Sun, Wenwen
    Wang, Yan
    Ren, Shengxiang
    Li, Xuefei
    Li, Jiayu
    Rivard, Christopher J.
    Zhou, Caicun
    Hirsch, Fred R.
    ONCOTARGETS AND THERAPY, 2016, 9 : 2409 - 2414
  • [20] Gemcitabine and nab-paclitaxel retreatment as a third-line therapy following second-line FOLFIRINOX for advanced pancreatic adenocarcinoma.
    Dean, Andrew Peter
    Das, Adarsh
    McNulty, Meabh
    Higgs, Domenic
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345